RM

Ritesh Madan

Active Director Director DIN 07967696
DIN 07967696 First appointment Dec 2017 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Dec 2017
Shareholding value •••• Premium profile

About Ritesh Madan

Data last updated:

Ritesh Madan is a Director at Crms Pharmaceutical Private Limited (since 2017). The company operates in Pharma. Crms Pharmaceutical Private Limited reported revenue of ₹89.9 Lakh (FY 2025).

DIN 07967696
Primary Designation Director
Industry Pharma
First Appointment 04 Dec 2017
Oldest Company Age 8 yrs
Largest company Crms Pharmaceutical Private Limited · ₹89.9 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Crms Pharmaceutical Private Limited U51909HR2017PTC071697
Director04 Dec 20172017₹89.9 Lakh (FY 2025)Active

Board colleagues of Ritesh Madan

Directorship timeline

Open interactive timeline →
Crms Pharmaceutical Private Limited
Premium access

Shareholding and investment profile for Ritesh Madan

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ritesh Madan

Ritesh Madan currently holds 1 directorship: Crms Pharmaceutical Private Limited (Director, since 04 Dec 2017, revenue ₹89.9 Lakh (FY 2025)).

Ritesh Madan was first appointed on 04 Dec 2017 as Director at Crms Pharmaceutical Private Limited.

The current boards of Ritesh Madan's companies include Raj Kumari (Crms Pharmaceutical Private Limited), Shefali (Crms Pharmaceutical Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available